Gastric Cancer Market By Disease Type, By Treatment Type, By Drug Class Outlook, By Route of Administration, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021-2031

List of Tables

The global gastric cancer market is anticipated to reach $10.7 billion by 2031, growing from $2.1 billion in 2021, at a CAGR of 17.9% from 2022 to 2031.

Gastric cancer is a disease in which malignant (cancer) cells form in the lining of the stomach. Age, diet, and sedentary lifestyle can lead to the risk of developing gastric cancer. Symptoms of gastric cancer include indigestion and stomach discomfort or pain. Tests that examine the stomach and esophagus are used to diagnose gastric cancer.

The gastric cancer market is expected to expand as cases of the stomach disease rise. The causes of stomach cancer have significantly increased due to additional risk factors such as an increase in obesity, increase in the consumption of highly processed foods, sugary beverages, smoking, genetic modification of genes, a family history of cancer, and consumption of alcohol. Furthermore, the rising incidence of gastric cancer is anticipated to continue and this trend is boosting the demand for efficient treatments. All these factors are projected to drive the market revenue growth during the forecast period.

Gastric cancer treatment can be expensive as there are numerous tests which need to be conducted, including surgery, radiation therapy, and diagnosis, and staging. Different tests and procedures, such as imaging studies, endoscopies, biopsies, and blood tests, are frequently required in the diagnosis and staging of gastric cancer. The cost of these tests can be high, and multiple doctor visits might be necessary. The market is predicted to be severely constrained by the high cost of treating gastric cancer.

The market for gastric cancer is projected to benefit due to the increase in healthcare awareness. People are more likely to seek medical attention and get screened for the disease as they become more aware of the risk factors linked to gastric cancer. More cases of gastric cancer can be discovered at an earlier stage owing to the increase in awareness. Early detection of gastric cancer is essential for effective treatment and better patient outcomes. Therefore, gastric cancer patient may need diagnostic and therapeutic options like medication, surgery, and radiation therapy. These factors are expected to create several growth opportunities for the major players operating in the market.

The COVID-19 pandemic had a detrimental effect on the treatment of gastric cancer, especially in terms of the timing of screening, diagnosis, and treatment.COVID-19 is an unprecedented global public health emergency that affected almost every industry, and the long-term impacts are projected to reflect on the growth of various end-use industries during the post-pandemic period. Many gastric cancer patients have experienced treatment interruptions due to the pandemic. To reduce the risk of COVID-19 transmission, treatment schedules had to be altered, which resulted in delays or changes to some patients' treatment plans. Concerns about COVID-19 exposure in healthcare settings made patients hesitant to seek treatment. Clinical trials for gastric cancer were significantly impacted by the pandemic as numerous clinical trials were postponed or delayed.

The key players profiled in this report include: Novartis AG, Pfizer, Inc., Mylan N.V., F. Hoffmann La Roche Ltd., Eli Lilly and Company, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Celltrion Healthcare Co., Ltd., Samsung Bioepis and Bristol Myers Squibb Company

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the gastric cancer market analysis from 2021 to 2031 to identify the prevailing gastric cancer market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the gastric cancer market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global gastric cancer market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Disease Type

Adenocarcinoma
Lymphoma
Gastrointestinal Stromal Tumor
Carcinoid Tumor
Others

By Treatment Type

Immunotherapy
Targeted Therapy
Chemotherapy
Radiation Therapy and Surgery

By Drug Class Outlook

PD-1/PD-L1 Inhibitors
HER2 Antagonists
VEGFR2 Antagonists
Others

By Route of Administration

Oral
Injectable

By Distribution Channel

Specialty and Retail Pharmacies
Others
Hospital Pharmacies

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- UK
- France
- Spain
- Italy
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia-Pacific
LAMEA
- Brazil
- United Arab Emirates
- Saudi Arabia
- South Africa
- Rest of LAMEA

Key Market Players:

Novartis AG
Pfizer, Inc.
Mylan N.V.
F. Hoffmann La Roche Ltd.
Eli Lilly And Company
Merck & Co., Inc.
Teva Pharmaceutical Industries Ltd.
Celltrion Healthcare Co., Ltd.
samsung bioepis
Bristol Myers Squibb Company

Product Code: A74458

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
3.3. Porter's five forces analysis
3.4. Market dynamics
- 3.4.1. Drivers
- 3.4.2. Restraints
- 3.4.3. Opportunities
3.5. COVID-19 Impact Analysis on the market
3.6. Average Selling Price
3.7. Brand Share Analysis
3.8. Key Regulation Analysis
3.9. Market Share Analysis
3.10. Patent Landscape
3.11. Regulatory Guidelines
3.12. Value Chain Analysis

CHAPTER 4: GASTRIC CANCER MARKET, BY DISEASE TYPE

4.1. Overview
- 4.1.1. Market size and forecast
4.2. Adenocarcinoma
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
4.3. Lymphoma
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
4.4. Gastrointestinal Stromal Tumor
- 4.4.1. Key market trends, growth factors and opportunities
- 4.4.2. Market size and forecast, by region
- 4.4.3. Market share analysis by country
4.5. Carcinoid Tumor
- 4.5.1. Key market trends, growth factors and opportunities
- 4.5.2. Market size and forecast, by region
- 4.5.3. Market share analysis by country
4.6. Others
- 4.6.1. Key market trends, growth factors and opportunities
- 4.6.2. Market size and forecast, by region
- 4.6.3. Market share analysis by country

CHAPTER 5: GASTRIC CANCER MARKET, BY TREATMENT TYPE

5.1. Overview
- 5.1.1. Market size and forecast
5.2. Immunotherapy
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
5.3. Targeted Therapy
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country
5.4. Chemotherapy
- 5.4.1. Key market trends, growth factors and opportunities
- 5.4.2. Market size and forecast, by region
- 5.4.3. Market share analysis by country
5.5. Radiation Therapy and Surgery
- 5.5.1. Key market trends, growth factors and opportunities
- 5.5.2. Market size and forecast, by region
- 5.5.3. Market share analysis by country

CHAPTER 6: GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK

6.1. Overview
- 6.1.1. Market size and forecast
6.2. PD-1/PD-L1 Inhibitors
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
6.3. HER2 Antagonists
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country
6.4. VEGFR2 Antagonists
- 6.4.1. Key market trends, growth factors and opportunities
- 6.4.2. Market size and forecast, by region
- 6.4.3. Market share analysis by country
6.5. Others
- 6.5.1. Key market trends, growth factors and opportunities
- 6.5.2. Market size and forecast, by region
- 6.5.3. Market share analysis by country

CHAPTER 7: GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION

7.1. Overview
- 7.1.1. Market size and forecast
7.2. Oral
- 7.2.1. Key market trends, growth factors and opportunities
- 7.2.2. Market size and forecast, by region
- 7.2.3. Market share analysis by country
7.3. Injectable
- 7.3.1. Key market trends, growth factors and opportunities
- 7.3.2. Market size and forecast, by region
- 7.3.3. Market share analysis by country

CHAPTER 8: GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL

8.1. Overview
- 8.1.1. Market size and forecast
8.2. Hospital Pharmacies
- 8.2.1. Key market trends, growth factors and opportunities
- 8.2.2. Market size and forecast, by region
- 8.2.3. Market share analysis by country
8.3. Specialty and Retail Pharmacies
- 8.3.1. Key market trends, growth factors and opportunities
- 8.3.2. Market size and forecast, by region
- 8.3.3. Market share analysis by country
8.4. Others
- 8.4.1. Key market trends, growth factors and opportunities
- 8.4.2. Market size and forecast, by region
- 8.4.3. Market share analysis by country

CHAPTER 9: GASTRIC CANCER MARKET, BY REGION

9.1. Overview
- 9.1.1. Market size and forecast By Region
9.2. North America
- 9.2.1. Key trends and opportunities
- 9.2.2. Market size and forecast, by Disease Type
- 9.2.3. Market size and forecast, by Treatment Type
- 9.2.4. Market size and forecast, by Drug Class Outlook
- 9.2.5. Market size and forecast, by Route of Administration
- 9.2.6. Market size and forecast, by Distribution Channel
- 9.2.7. Market size and forecast, by country
  - 9.2.7.1. U.S.
  - 9.2.7.1.1. Key market trends, growth factors and opportunities
  - 9.2.7.1.2. Market size and forecast, by Disease Type
  - 9.2.7.1.3. Market size and forecast, by Treatment Type
  - 9.2.7.1.4. Market size and forecast, by Drug Class Outlook
  - 9.2.7.1.5. Market size and forecast, by Route of Administration
  - 9.2.7.1.6. Market size and forecast, by Distribution Channel
  - 9.2.7.2. Canada
  - 9.2.7.2.1. Key market trends, growth factors and opportunities
  - 9.2.7.2.2. Market size and forecast, by Disease Type
  - 9.2.7.2.3. Market size and forecast, by Treatment Type
  - 9.2.7.2.4. Market size and forecast, by Drug Class Outlook
  - 9.2.7.2.5. Market size and forecast, by Route of Administration
  - 9.2.7.2.6. Market size and forecast, by Distribution Channel
  - 9.2.7.3. Mexico
  - 9.2.7.3.1. Key market trends, growth factors and opportunities
  - 9.2.7.3.2. Market size and forecast, by Disease Type
  - 9.2.7.3.3. Market size and forecast, by Treatment Type
  - 9.2.7.3.4. Market size and forecast, by Drug Class Outlook
  - 9.2.7.3.5. Market size and forecast, by Route of Administration
  - 9.2.7.3.6. Market size and forecast, by Distribution Channel
9.3. Europe
- 9.3.1. Key trends and opportunities
- 9.3.2. Market size and forecast, by Disease Type
- 9.3.3. Market size and forecast, by Treatment Type
- 9.3.4. Market size and forecast, by Drug Class Outlook
- 9.3.5. Market size and forecast, by Route of Administration
- 9.3.6. Market size and forecast, by Distribution Channel
- 9.3.7. Market size and forecast, by country
  - 9.3.7.1. Germany
  - 9.3.7.1.1. Key market trends, growth factors and opportunities
  - 9.3.7.1.2. Market size and forecast, by Disease Type
  - 9.3.7.1.3. Market size and forecast, by Treatment Type
  - 9.3.7.1.4. Market size and forecast, by Drug Class Outlook
  - 9.3.7.1.5. Market size and forecast, by Route of Administration
  - 9.3.7.1.6. Market size and forecast, by Distribution Channel
  - 9.3.7.2. UK
  - 9.3.7.2.1. Key market trends, growth factors and opportunities
  - 9.3.7.2.2. Market size and forecast, by Disease Type
  - 9.3.7.2.3. Market size and forecast, by Treatment Type
  - 9.3.7.2.4. Market size and forecast, by Drug Class Outlook
  - 9.3.7.2.5. Market size and forecast, by Route of Administration
  - 9.3.7.2.6. Market size and forecast, by Distribution Channel
  - 9.3.7.3. France
  - 9.3.7.3.1. Key market trends, growth factors and opportunities
  - 9.3.7.3.2. Market size and forecast, by Disease Type
  - 9.3.7.3.3. Market size and forecast, by Treatment Type
  - 9.3.7.3.4. Market size and forecast, by Drug Class Outlook
  - 9.3.7.3.5. Market size and forecast, by Route of Administration
  - 9.3.7.3.6. Market size and forecast, by Distribution Channel
  - 9.3.7.4. Spain
  - 9.3.7.4.1. Key market trends, growth factors and opportunities
  - 9.3.7.4.2. Market size and forecast, by Disease Type
  - 9.3.7.4.3. Market size and forecast, by Treatment Type
  - 9.3.7.4.4. Market size and forecast, by Drug Class Outlook
  - 9.3.7.4.5. Market size and forecast, by Route of Administration
  - 9.3.7.4.6. Market size and forecast, by Distribution Channel
  - 9.3.7.5. Italy
  - 9.3.7.5.1. Key market trends, growth factors and opportunities
  - 9.3.7.5.2. Market size and forecast, by Disease Type
  - 9.3.7.5.3. Market size and forecast, by Treatment Type
  - 9.3.7.5.4. Market size and forecast, by Drug Class Outlook
  - 9.3.7.5.5. Market size and forecast, by Route of Administration
  - 9.3.7.5.6. Market size and forecast, by Distribution Channel
  - 9.3.7.6. Rest of Europe
  - 9.3.7.6.1. Key market trends, growth factors and opportunities
  - 9.3.7.6.2. Market size and forecast, by Disease Type
  - 9.3.7.6.3. Market size and forecast, by Treatment Type
  - 9.3.7.6.4. Market size and forecast, by Drug Class Outlook
  - 9.3.7.6.5. Market size and forecast, by Route of Administration
  - 9.3.7.6.6. Market size and forecast, by Distribution Channel
9.4. Asia-Pacific
- 9.4.1. Key trends and opportunities
- 9.4.2. Market size and forecast, by Disease Type
- 9.4.3. Market size and forecast, by Treatment Type
- 9.4.4. Market size and forecast, by Drug Class Outlook
- 9.4.5. Market size and forecast, by Route of Administration
- 9.4.6. Market size and forecast, by Distribution Channel
- 9.4.7. Market size and forecast, by country
  - 9.4.7.1. China
  - 9.4.7.1.1. Key market trends, growth factors and opportunities
  - 9.4.7.1.2. Market size and forecast, by Disease Type
  - 9.4.7.1.3. Market size and forecast, by Treatment Type
  - 9.4.7.1.4. Market size and forecast, by Drug Class Outlook
  - 9.4.7.1.5. Market size and forecast, by Route of Administration
  - 9.4.7.1.6. Market size and forecast, by Distribution Channel
  - 9.4.7.2. Japan
  - 9.4.7.2.1. Key market trends, growth factors and opportunities
  - 9.4.7.2.2. Market size and forecast, by Disease Type
  - 9.4.7.2.3. Market size and forecast, by Treatment Type
  - 9.4.7.2.4. Market size and forecast, by Drug Class Outlook
  - 9.4.7.2.5. Market size and forecast, by Route of Administration
  - 9.4.7.2.6. Market size and forecast, by Distribution Channel
  - 9.4.7.3. India
  - 9.4.7.3.1. Key market trends, growth factors and opportunities
  - 9.4.7.3.2. Market size and forecast, by Disease Type
  - 9.4.7.3.3. Market size and forecast, by Treatment Type
  - 9.4.7.3.4. Market size and forecast, by Drug Class Outlook
  - 9.4.7.3.5. Market size and forecast, by Route of Administration
  - 9.4.7.3.6. Market size and forecast, by Distribution Channel
  - 9.4.7.4. South Korea
  - 9.4.7.4.1. Key market trends, growth factors and opportunities
  - 9.4.7.4.2. Market size and forecast, by Disease Type
  - 9.4.7.4.3. Market size and forecast, by Treatment Type
  - 9.4.7.4.4. Market size and forecast, by Drug Class Outlook
  - 9.4.7.4.5. Market size and forecast, by Route of Administration
  - 9.4.7.4.6. Market size and forecast, by Distribution Channel
  - 9.4.7.5. Australia
  - 9.4.7.5.1. Key market trends, growth factors and opportunities
  - 9.4.7.5.2. Market size and forecast, by Disease Type
  - 9.4.7.5.3. Market size and forecast, by Treatment Type
  - 9.4.7.5.4. Market size and forecast, by Drug Class Outlook
  - 9.4.7.5.5. Market size and forecast, by Route of Administration
  - 9.4.7.5.6. Market size and forecast, by Distribution Channel
  - 9.4.7.6. Rest of Asia-Pacific
  - 9.4.7.6.1. Key market trends, growth factors and opportunities
  - 9.4.7.6.2. Market size and forecast, by Disease Type
  - 9.4.7.6.3. Market size and forecast, by Treatment Type
  - 9.4.7.6.4. Market size and forecast, by Drug Class Outlook
  - 9.4.7.6.5. Market size and forecast, by Route of Administration
  - 9.4.7.6.6. Market size and forecast, by Distribution Channel
9.5. LAMEA
- 9.5.1. Key trends and opportunities
- 9.5.2. Market size and forecast, by Disease Type
- 9.5.3. Market size and forecast, by Treatment Type
- 9.5.4. Market size and forecast, by Drug Class Outlook
- 9.5.5. Market size and forecast, by Route of Administration
- 9.5.6. Market size and forecast, by Distribution Channel
- 9.5.7. Market size and forecast, by country
  - 9.5.7.1. Brazil
  - 9.5.7.1.1. Key market trends, growth factors and opportunities
  - 9.5.7.1.2. Market size and forecast, by Disease Type
  - 9.5.7.1.3. Market size and forecast, by Treatment Type
  - 9.5.7.1.4. Market size and forecast, by Drug Class Outlook
  - 9.5.7.1.5. Market size and forecast, by Route of Administration
  - 9.5.7.1.6. Market size and forecast, by Distribution Channel
  - 9.5.7.2. United Arab Emirates
  - 9.5.7.2.1. Key market trends, growth factors and opportunities
  - 9.5.7.2.2. Market size and forecast, by Disease Type
  - 9.5.7.2.3. Market size and forecast, by Treatment Type
  - 9.5.7.2.4. Market size and forecast, by Drug Class Outlook
  - 9.5.7.2.5. Market size and forecast, by Route of Administration
  - 9.5.7.2.6. Market size and forecast, by Distribution Channel
  - 9.5.7.3. Saudi Arabia
  - 9.5.7.3.1. Key market trends, growth factors and opportunities
  - 9.5.7.3.2. Market size and forecast, by Disease Type
  - 9.5.7.3.3. Market size and forecast, by Treatment Type
  - 9.5.7.3.4. Market size and forecast, by Drug Class Outlook
  - 9.5.7.3.5. Market size and forecast, by Route of Administration
  - 9.5.7.3.6. Market size and forecast, by Distribution Channel
  - 9.5.7.4. South Africa
  - 9.5.7.4.1. Key market trends, growth factors and opportunities
  - 9.5.7.4.2. Market size and forecast, by Disease Type
  - 9.5.7.4.3. Market size and forecast, by Treatment Type
  - 9.5.7.4.4. Market size and forecast, by Drug Class Outlook
  - 9.5.7.4.5. Market size and forecast, by Route of Administration
  - 9.5.7.4.6. Market size and forecast, by Distribution Channel
  - 9.5.7.5. Rest of LAMEA
  - 9.5.7.5.1. Key market trends, growth factors and opportunities
  - 9.5.7.5.2. Market size and forecast, by Disease Type
  - 9.5.7.5.3. Market size and forecast, by Treatment Type
  - 9.5.7.5.4. Market size and forecast, by Drug Class Outlook
  - 9.5.7.5.5. Market size and forecast, by Route of Administration
  - 9.5.7.5.6. Market size and forecast, by Distribution Channel

CHAPTER 10: COMPETITIVE LANDSCAPE

10.1. Introduction
10.2. Top winning strategies
10.3. Product Mapping of Top 10 Player
10.4. Competitive Dashboard
10.5. Competitive Heatmap
10.6. Top player positioning, 2021

CHAPTER 11: COMPANY PROFILES

11.1. Novartis AG
- 11.1.1. Company overview
- 11.1.2. Key Executives
- 11.1.3. Company snapshot
11.2. Pfizer, Inc.
- 11.2.1. Company overview
- 11.2.2. Key Executives
- 11.2.3. Company snapshot
11.3. Mylan N.V.
- 11.3.1. Company overview
- 11.3.2. Key Executives
- 11.3.3. Company snapshot
11.4. F. Hoffmann La Roche Ltd.
- 11.4.1. Company overview
- 11.4.2. Key Executives
- 11.4.3. Company snapshot
11.5. Eli Lilly And Company
- 11.5.1. Company overview
- 11.5.2. Key Executives
- 11.5.3. Company snapshot
11.6. Merck & Co., Inc.
- 11.6.1. Company overview
- 11.6.2. Key Executives
- 11.6.3. Company snapshot
11.7. Teva Pharmaceutical Industries Ltd.
- 11.7.1. Company overview
- 11.7.2. Key Executives
- 11.7.3. Company snapshot
11.8. Celltrion Healthcare Co., Ltd.
- 11.8.1. Company overview
- 11.8.2. Key Executives
- 11.8.3. Company snapshot
11.9. samsung bioepis
- 11.9.1. Company overview
- 11.9.2. Key Executives
- 11.9.3. Company snapshot
11.10. Bristol Myers Squibb Company
- 11.10.1. Company overview
- 11.10.2. Key Executives
- 11.10.3. Company snapshot